Tune Therapeutics, a US startup, has developed a unique genetic tuning platform called TEMPO, which allows for precise, adjustable, and reversible control of gene behavior. Unlike traditional gene editing, TEMPO uses two switchable components: the DNA-binding domain (DBD) and effectors. The DBD targets specific genomic sites, while the effectors modify epigenetic marks to regulate gene activity. This customization enables TEMPO to precisely control gene expression, providing versatile therapeutic solutions.